ADAR1 Capital Quietly Builds 800,000‑Share Stake in InMed Pharmaceuticals Amid Volatile Cannabis‑Based Biotech Stock

ADAR1 Capital’s Latest Move: A Quiet Accumulation Amid Volatile Shares

On July 15, 2026, ADAR1 Capital Management, LLC added 1,000 shares of InMed Pharmaceuticals to its portfolio at $1.56, bringing its post‑transaction holdings to 801,000 shares. The purchase, executed at a price only marginally below the market close of $1.59, is part of a series of buy‑side actions that have seen ADAR1 steadily build a sizable stake in the cannabis‑based biopharma. While the trade itself is small relative to the company’s $5.3 million market cap, its timing and context warrant attention.

Implications for Investors

The incremental build by ADAR1 signals confidence in InMed’s long‑term prospects. Historically, the fund has accumulated shares at prices ranging from $1.50 to $1.60, consistently aligning with periods of modest price dips. This pattern suggests a patient‑capital strategy aimed at capitalizing on short‑term volatility rather than reacting to headline events. For investors, the move could be interpreted as an endorsement of the company’s pipeline and commercialization strategy, especially as InMed continues to develop its proprietary cannabinoid platform. However, the firm’s negative earnings ratio and a 42% annual decline in price underscore the inherent risk in a nascent biotech with a narrow revenue base. Stakeholders should monitor whether ADAR1’s accumulation translates into board influence or partnership opportunities that could accelerate product development.

What the Insider Activity Tells Us About the Company’s Future

InMed’s insider activity remains largely driven by institutional buyers, notably Vivo Opportunity and its affiliates, who have been the largest purchasers in recent months. Their consistent buying—often in the 30,000–50,000‑share blocks—indicates a long‑term belief in the company’s potential, even as the share price has slid below the 52‑week low of $0.58. The fact that these institutional investors continue to acquire shares at a price near $1.55 suggests that they see value in the company’s research pipeline, perhaps anticipating a breakthrough in its cannabinoid therapeutics. For the company, this sustained interest can help maintain liquidity and provide a cushion against further price erosion, but it also places pressure on management to deliver tangible milestones to justify continued investment.

Profile of ADAR1 Capital Management, LLC

ADAR1 Capital operates as a private investment vehicle focused on high‑growth biotechnology and healthcare sectors. Its transaction history with InMed shows a disciplined accumulation strategy: three sizable purchases on May 19, 2026 (68,551, 200,000, and 200,000 shares) followed by the recent July 15 buy. Prices hovered between $1.50 and $1.60, reflecting a willingness to pay slightly above market when it believes in the company’s future cash flows. The fund’s holdings post‑transaction consistently settle near the 800,000‑share mark, indicating a target stake that balances influence with exposure. ADAR1’s approach is data‑driven, favoring companies with proprietary technology platforms and a clear regulatory pathway, rather than chasing short‑term price swings. This patient‑capital mindset may bode well for InMed as it navigates the complex path from research to commercialization.

Bottom Line for Market Watchers

ADAR1’s latest purchase is a modest yet meaningful addition to a growing position in InMed, reinforcing the narrative that institutional investors see long‑term value despite current valuation challenges. The company’s continued reliance on institutional buying, coupled with a robust pipeline of cannabinoid‑based therapies, could position it favorably if key clinical milestones are met. Investors should keep an eye on future insider disclosures and earnings reports to gauge whether the confidence shown by ADAR1 and Vivo Opportunity translates into tangible progress and a rebound in share price.